Log in to the research portal to view current pricing, stock, and bundles and order.
Growth Hormone & Muscle research peptides in this catalog
The hypothalamic-pituitary GH axis and why secretagogues are studied
Growth hormone secretion in mammals is governed by a feedback loop among three signals. The hypothalamus releases growth hormone-releasing hormone (GHRH), which stimulates somatotroph cells in the anterior pituitary to synthesize and release GH. Opposing this, the hypothalamus also releases somatostatin (somatotropin release-inhibiting factor), which suppresses somatotroph output. Layered on top is the ghrelin pathway: the stomach-derived peptide ghrelin acts on the growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus to amplify GH release through a route distinct from GHRH.
Because GH is released in discrete pulses rather than as a steady stream, researchers studying the axis are interested in tools that probe pulsatile dynamics, receptor specificity, and feedback regulation. Synthetic peptides that mimic GHRH or ghrelin let investigators isolate one limb of the loop at a time. This is the core scientific reason these compounds appear so often in endocrinology and muscle-physiology literature: each one interrogates a defined node of the axis, allowing controlled study of somatotroph behavior, IGF-1 induction, and downstream anabolic signaling in cell and animal models.
Two distinct mechanisms: GHRH analogs versus ghrelin-mimetic secretagogues
CJC-1295 is a synthetic analog of GHRH. In research models it binds the GHRH receptor on pituitary somatotrophs and is studied for its capacity to extend the duration of GHRH-type signaling. Some CJC-1295 constructs incorporate a Drug Affinity Complex (DAC) modification that has been reported in the literature to bind serum albumin and lengthen the molecule's circulating half-life, prolonging exposure of the receptor to a GHRH-like stimulus. The mechanistic question studied here is how a longer-acting GHRH signal reshapes the amplitude and frequency of GH pulses compared with native GHRH.
By contrast, Ipamorelin, GHRP-6, GHRP-2, and Hexarelin are growth hormone secretagogues that act on the ghrelin receptor (GHS-R1a) rather than the GHRH receptor. In preclinical studies they are reported to trigger GH release through the ghrelin pathway and, in several models, to transiently suppress somatostatin tone. Because the GHRH limb and the ghrelin limb are independent, researchers frequently study a GHRH analog and a ghrelin-mimetic together to observe whether the two stimuli combine additively or synergistically on somatotroph output.
Selectivity profiles: a clean secretagogue versus appetite-linked signaling
Within the ghrelin-receptor class, the listed peptides differ markedly in their reported off-target signaling. Ipamorelin is characterized in the literature as a selective GHS-R1a agonist studied for releasing GH in animal models with comparatively little reported effect on cortisol, prolactin, or appetite-related circuits. This relatively narrow profile is the reason Ipamorelin is often selected as a research tool when investigators want to study GH release with minimal confounding from other hormonal axes.
GHRP-6 sits at the other end of the spectrum: in animal studies it is reported to stimulate GH release and also to drive pronounced appetite-related and food-intake signaling through the ghrelin system, making it a useful probe for studying the orexigenic dimension of GHS-R1a activation. GHRP-2 is described as a potent GH secretagogue with intermediate secondary signaling, and Hexarelin is studied both for robust GH release and for reported cardiovascular and CD36-receptor interactions that are independent of GH itself. These differing profiles let researchers dissect which downstream effects are GH-mediated and which arise from the receptor directly.
IGF-1 LR3: studying the downstream effector directly
Most of the molecules in this category act upstream, prompting the pituitary to release endogenous GH, which in turn induces hepatic and peripheral production of insulin-like growth factor 1 (IGF-1). IGF-1 LR3 takes a different approach by representing the effector itself. It is a recombinant analog of IGF-1 in which an Arg3 substitution and a 13-amino-acid N-terminal extension are reported to reduce binding to IGF-binding proteins (IGFBPs), which in native systems sequester circulating IGF-1.
In cell-culture and animal research, reduced IGFBP binding is studied as a way to prolong the molecule's interaction with the IGF-1 receptor, allowing investigators to examine IGF-1 receptor signaling cascades, PI3K/Akt and MAPK pathway activation, and myocyte proliferation and differentiation without first having to stimulate the GH axis. IGF-1 LR3 therefore functions as a downstream tool that complements the upstream secretagogues: one set of compounds asks how GH is released, while IGF-1 LR3 asks what the principal anabolic mediator does once it reaches its receptor.
Research application areas across the class
Across published preclinical work, these peptides recur in a consistent set of investigative contexts. Endocrinology laboratories use them to map somatotroph receptor pharmacology and to model pulsatile GH secretion. Muscle-physiology and cell-biology groups use them in myocyte and myoblast cultures to study anabolic signaling, protein-synthesis pathways, and satellite-cell behavior. Comparative pharmacology studies use the differing selectivity profiles to attribute observed effects to specific receptors.
Because the GHRH and ghrelin pathways feed into the same downstream IGF-1 axis, the category as a whole supports research questions about feedback regulation, somatostatin counter-regulation, and how upstream pulse patterns translate into IGF-1 exposure and tissue-level response. All of this work is conducted in vitro or in animal models for research purposes only.
Combination rationale studied in the literature
A recurring theme in preclinical literature is the pairing of a GHRH analog with a ghrelin-receptor secretagogue, most commonly modeled as CJC-1295 alongside Ipamorelin. The scientific rationale is mechanistic: because CJC-1295 engages the GHRH receptor while Ipamorelin engages GHS-R1a and can blunt somatostatin tone, the two stimuli act on separate control points of the same axis. Researchers study this pairing to observe whether simultaneous activation of both limbs produces a GH-release response greater than either stimulus alone.
Ipamorelin is frequently the secretagogue chosen for these paired models specifically because of its narrow selectivity: keeping cortisol, prolactin, and appetite signaling relatively constant lets investigators attribute changes in GH output to the combined receptor stimulus rather than to confounding hormonal effects. The same logic explains why a less selective peptide like GHRP-6 might instead be selected when the research question concerns appetite signaling rather than clean GH dynamics. These combinations are described strictly as experimental designs in research models, not as protocols for any living subject.
Reconstitution, storage, and purity considerations for research
Peptides in this category are typically supplied as lyophilized (freeze-dried) powder, the form in which they are most stable for shipping and storage. Research literature and handling references generally describe reconstitution with bacteriostatic or sterile water for laboratory preparation, with gentle handling to avoid mechanical degradation of the peptide chain. Reconstituted material is generally described as less stable than the lyophilized form and is handled accordingly in research settings.
Storage conditions reported for these compounds emphasize keeping lyophilized powder cold and protected from light and moisture, with colder long-term storage for extended holding periods. Purity is a central variable in any peptide research: analytical characterization by HPLC and mass spectrometry is the standard way labs confirm identity and percentage purity, since impurities and degradation products can confound experimental readouts. All such handling pertains exclusively to laboratory research use; these materials are not for human or animal consumption and are not FDA approved.
Research application areas
Choosing a compound for your research
Choose a GHRH analog (CJC-1295) when the research question concerns the GHRH-receptor limb of the axis or the effect of prolonging a GHRH-type signal on GH pulse dynamics.
Choose Ipamorelin when a clean, selective GHS-R1a probe is needed and minimizing cortisol, prolactin, and appetite-related confounders is important to the experimental readout.
Choose GHRP-6 when the study specifically targets ghrelin-driven appetite and food-intake signaling alongside GH release.
Choose GHRP-2 when a potent GH secretagogue with intermediate secondary signaling is the appropriate tool for the model.
Choose Hexarelin when investigating robust GH release together with reported cardiovascular or CD36-receptor interactions independent of GH.
Choose IGF-1 LR3 when the question is downstream of the pituitary, focusing directly on IGF-1 receptor signaling and myocyte response rather than on GH secretion.
Consider a GHRH-analog-plus-secretagogue pairing (e.g., CJC-1295 with Ipamorelin) when the experimental goal is to study dual-pathway activation of the same axis.
Confirm analytical purity (HPLC and mass spectrometry data) for any compound, since impurities can confound research readouts across all of these applications.
Per-compound reference data: Ipamorelin reference · IGF-1 LR3 reference.
Frequently asked questions
What is the difference between a GHRH analog and a growth hormone secretagogue?
A GHRH analog such as CJC-1295 binds the GHRH receptor on pituitary somatotrophs, mimicking the hypothalamic signal that normally prompts GH synthesis and release. Growth hormone secretagogues such as Ipamorelin, GHRP-6, GHRP-2, and Hexarelin instead bind the ghrelin receptor (GHS-R1a), a separate pathway that can also blunt somatostatin. Because the two act on independent receptors, they are studied separately or together in preclinical models. All such study is for research use only.
Why is Ipamorelin described as more selective than GHRP-6?
In published animal research, Ipamorelin is reported to stimulate GH release through GHS-R1a with comparatively little effect on cortisol, prolactin, or appetite-related signaling. GHRP-6, while also a GH secretagogue, is reported to drive pronounced appetite and food-intake signaling through the same receptor. This makes Ipamorelin a cleaner probe for isolating GH dynamics and GHRP-6 a useful tool for studying orexigenic effects. These are research-model observations, not effects in humans.
How does IGF-1 LR3 differ from the other peptides in this category?
Most peptides here act upstream, prompting the pituitary to release GH, which then induces IGF-1. IGF-1 LR3 is an analog of IGF-1 itself, the downstream effector. An Arg3 substitution and a 13-residue N-terminal extension are reported to reduce its binding to IGF-binding proteins, which in research models prolongs interaction with the IGF-1 receptor. It is used to study IGF-1 receptor signaling directly. It is for laboratory research only and is not FDA approved.
What is the scientific rationale for pairing CJC-1295 with Ipamorelin in research?
CJC-1295 engages the GHRH receptor while Ipamorelin engages the ghrelin receptor and can reduce somatostatin tone. Because these are separate control points on the same GH axis, researchers model the pairing to observe whether combined activation produces a greater somatotroph response than either stimulus alone. Ipamorelin's narrow selectivity helps attribute any change to the combined receptor stimulus. This describes an experimental design in research models, not a protocol for any living subject.
How are these lyophilized peptides handled in a research setting?
They are typically supplied as freeze-dried (lyophilized) powder, the most stable form for storage. Research handling references describe reconstitution with bacteriostatic or sterile water using gentle technique to avoid degrading the peptide. Lyophilized powder is generally kept cold and shielded from light and moisture, with colder storage for long-term holding. Reconstituted material is considered less stable. All handling is strictly for in-vitro laboratory research.
Why does purity matter when selecting research peptides?
Impurities and degradation byproducts can confound experimental readouts, making it difficult to attribute an observed effect to the intended compound. Laboratories typically rely on analytical characterization by HPLC and mass spectrometry to confirm a peptide's identity and percentage purity before use. Verifying this documentation is part of sound research practice across every application in this category. These materials are for research use only and are not intended for human or animal consumption.
Create a free research account to view current pricing, real-time stock, and bundle options, then submit your order for approval.
Related: What are peptides? · Reference library · Cost & pricing · Price comparison · Research guides · Order portal